Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28354165 | 0.98 | SLC18A3 (0.31) | SLC18A3SIGMAR1 | |
| SCHEMBL3828819 | 0.98 | SLC18A3 (0.31) | SLC18A3SIGMAR1 | |
| SCHEMBL29859614 | 0.82 | SLC18A3 (0.35) | SLC18A3SIGMAR1 | |
| SCHEMBL165871 | 0.79 | — | — | |
| SCHEMBL23223078 | 0.78 | — | — | |
| SCHEMBL28493181 | 0.78 | — | — | |
| Piperazine SCHEMBL27877942 | 0.73 | — | — | |
| SCHEMBL4754795 | 0.72 | — | — | |
| SCHEMBL11529807 | 0.69 | — | — | |
| SCHEMBL7380608 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457247-A | Synthesis method of dextromethorphan chiral intermediate | 江苏宝众宝达药业有限公司 | 2021-03-09 | — | — | CN | claimed |
| US-8115002-B2 | Preparation of substituted morphinan-6-ones and salts and intermediates thereof | MALLINCKRODT LLC (US) | 2012-02-14 | — | — | US | claimed |
| EP-2099764-B1 | PREPARATION OF SUBSTITUTED MORPHINAN-6-ONES AND SALTS AND INTERMEDIATES THEREOF | MALLINCKRODT INC (US) | 2011-07-27 | — | — | EP | claimed |
| US-20100048906-A1 | Preparation of Substituted Morphinan-6-Ones and Salts and Intermediates Thereof | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-02-25 | — | — | US | claimed |
| EP-2149559-A1 | A process for the preparation of hexahydroisoquinolines from 1,2,3,4-Tetrahydroisoquinolines | Mallinckrodt Inc. (US) | 2010-02-03 | — | — | EP | claimed |
| US-20090247756-A1 | Process for the Preparation of Hexahydroisoquinolines from 1,2,3,4-Tetrahydroisoquinolines | MALLINCKRODT INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2102163-A2 | PREPARATION OF HEXAHYDROISOQUINOLINES FROM DIHYDROISOQUINOLINES | Mallinckrodt Inc. (US) | 2009-09-23 | — | — | EP | claimed |
| EP-2099764-A1 | PREPARATION OF SUBSTITUTED MORPHINAN-6-ONES AND SALTS AND INTERMEDIATES THEREOF | Mallinckrodt Inc. (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073389-A2 | PREPARATION OF HEXAHYDROISOQUINOLINES FROM DIHYDROISOQUINOLINES | MALLINCKRODT INC. (US) | 2008-06-19 | — | — | WO | claimed |
| WO-2008036172-A1 | PREPARATION OF SUBSTITUTED MORPHINAN-6-ONES AND SALTS AND INTERMEDIATES THEREOF | MALLINCKRODT INC. (US) | 2008-03-27 | — | — | WO | claimed |
| EP-1861373-A2 | PROCESSES FOR PREPARING MORPHINANS AND INTERMEDIATES THEREOF | MALLINCKRODT, INC. (US) | 2007-12-05 | — | — | EP | claimed |
| WO-2006098855-A2 | PROCESSES FOR PREPARING MORPHINANS AND INTERMEDIATES THEREOF | MALLINCKRODT INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-4368326-A | Short total synthesis of dihydrothebainone, dihydrocodeinone, and nordihydroccodeinone | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 1983-01-11 | — | — | US | claimed |
| JP-10114775-A | — | — | None | — | — | JP | disclosed |
| WO-2025201708-A1 | INGRILIMINE AND DERIVATIVES, INVOLVEMENT IN NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-10-02 | — | — | WO | disclosed |
| EP-4624457-A1 | INGRILIMINE AND DERIVATIVES, INVOLVEMENT IN NEURODEGENERATIVE DISEASES | Centre National de la Recherche Scientifique (FR) | 2025-10-01 | — | — | EP | disclosed |
| US-4334070-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1982-06-08 | — | — | US | disclosed |
| EP-0035244-A2 | Cycloalka(4,5)pyrrolo(2,3-g)isoquinolines, processes and intermediates for their preparation, and medicines containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-09-09 | — | — | EP | disclosed |
| US-4260762-A | NEUROLEPTICS | HOFFMANN-LA ROCHE INC. (US) | 1981-04-07 | — | — | US | disclosed |
| EP-0010661-A2 | Isoquinoline derivatives, process for their preparation, intermediates and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247756-A1 | Process for the Preparation of Hexahydroisoquinolines from 1,2,3,4-Tetrahydroisoquinolines | INF2, TYR, MDM2 | SLC18A3 4210/4885SIGMAR1 3448/4885 |
| US-20100048906-A1 | Preparation of Substituted Morphinan-6-Ones and Salts and Intermediates Thereof | CYP2D6, RTN4, UGT1A6 | SLC18A3 1410/4885SIGMAR1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.